Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention.
Sepideh MirzaeiMahshid Deldar Abad PaskehElena OkinaMohammad Hossein GholamiKiavash HushmandiMehrdad HashemiAzuma KaluAli ZarrabiNoushin NabaviNavid RabieeEsmaeel SharifiHassan Karimi-MalehMilad AshrafizadehAlan Prem KumarYuzhuo Z WangPublished in: Journal of experimental & clinical cancer research : CR (2022)
The aberrant expression of lncRNAs in prostate cancer has been well-documented and progression rate of tumor cells are regulated via affecting STAT3, NF-κB, Wnt, PI3K/Akt and PTEN, among other molecular pathways. Furthermore, lncRNAs regulate radio-resistance and chemo-resistance features of prostate tumor cells. Overexpression of tumor-promoting lncRNAs such as HOXD-AS1 and CCAT1 can result in drug resistance. Besides, lncRNAs can induce immune evasion of prostate cancer via upregulating PD-1. Pharmacological compounds such as quercetin and curcumin have been applied for targeting lncRNAs. Furthermore, siRNA tool can reduce expression of lncRNAs thereby suppressing prostate cancer progression. Prognosis and diagnosis of prostate tumor at clinical course can be evaluated by lncRNAs. The expression level of exosomal lncRNAs such as lncRNA-p21 can be investigated in serum of prostate cancer patients as a reliable biomarker.
Keyphrases
- prostate cancer
- pi k akt
- radical prostatectomy
- network analysis
- cell proliferation
- signaling pathway
- genome wide analysis
- genome wide identification
- poor prognosis
- stem cells
- transcription factor
- photodynamic therapy
- oxidative stress
- squamous cell carcinoma
- single cell
- drug delivery
- locally advanced
- benign prostatic hyperplasia
- cell death
- toll like receptor
- atomic force microscopy